Julius Clinical International
Julius Clinical International is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D
Sponsor Princess Maxima Center For Pediatric Oncology
- Start (EU)
- Latest update
- Estimated end
LBL 2018 – International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus
Sponsor Marinus Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol C
Sponsor Princess Maxima Center For Pediatric Oncology
- Start (EU)
- Latest update
- Estimated end
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children – sub protocol B
Sponsor Princess Maxima Center For Pediatric Oncology
- Start (EU)
- Latest update
- Estimated end
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML
Sponsor Prinses Maxima Centrum voor Kinderoncologie B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia
Sponsor Associazione Italiana Ematologia Oncologia Pediatrica
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)
Sponsor Prinses Maxima Centrum voor Kinderoncologie B.V.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Sponsor Amylyx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in patients with focal (partial onset) seizures
Sponsor Engrail Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Julius Clinical International?
The 2026-10-09 snapshot links Julius Clinical International to 16 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Regulatory services, Data management, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Julius Clinical International?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Julius Clinical International conducted?
The linked trials record locations in 22 countries, including Netherlands, Germany, Denmark, Spain, Italy. These are trial locations, not confirmed office locations or countries where Julius Clinical International delivered services.
What can this page tell me about Julius Clinical International's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Julius Clinical International. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Julius Clinical International B.V.